
## **Given Names Deactivated Family Name**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2255058/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort. Psychological Medicine, 2023, 53, 66-77.	2.7	8
2	Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort. Psychological Medicine, 2023, 53, 1891-1905.	2.7	3
3	Metabolic syndrome and related factors in a large sample of antipsychotic naÃ <sup>-</sup> ve patients with first-episode psychosis: 3 years follow-up results from the PAFIP cohort. Revista De PsiquiatrÃa Y Salud Mental, 2023, 16, 175-183.	1.0	1
4	Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort. Psychological Medicine, 2022, 52, 770-779.	2.7	5
5	Clinical characterization of brief psychotic disorders triggered by the COVID-19 pandemic: a multicenter observational study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 5-15.	1.8	19
6	Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. Pharmacopsychiatry, 2022, 55, 40-47.	1.7	11
7	Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. Revista De PsiquiatrÃa Y Salud Mental, 2022, 15, 117-133.	1.0	2
8	A <scp>metaâ€analysis</scp> of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the <scp>ENIGMA Consortium</scp> . Human Brain Mapping, 2022, 43, 352-372.	1.9	39
9	Routine cerebrospinal fluid parameters as biomarkers in first-episode psychosis: A prospective observational study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 112, 110424.	2.5	13
10	Examining the relationship between psychosis and immigration in Spain: The effect of cannabis use and language barrier in a large psychosis sample. Journal of Psychiatric Research, 2022, 145, 361-365.	1.5	1
11	Multi-scale semi-supervised clustering of brain images: Deriving disease subtypes. Medical Image Analysis, 2022, 75, 102304.	7.0	28
12	Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain. Psychiatry Research, 2022, 308, 114352.	1.7	4
13	Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study. Journal of Affective Disorders, 2022, 300, 99-108.	2.0	3
14	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. JAMA Psychiatry, 2022, 79, 260.	6.0	44
15	Trauma and stressor-related disorders among health care workers during COVID-19 pandemic and the role of the gender: A prospective longitudinal survey Journal of Affective Disorders, 2022, 302, 110-122.	2.0	14
16	Disentangling early and late onset of psychosis in women: identifying new targets for treatment. Archives of Women's Mental Health, 2022, 25, 335-344.	1.2	3
17	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. Biological Psychiatry, 2022, 92, 299-313.	0.7	11
18	A proxy measure of premorbid adjustment in psychosis for large-scale epidemiological studies and electronic health record-based research. Schizophrenia Research, 2022, 243, 467-469.	1.1	3

#	Article	IF	CITATIONS
19	Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders. Acta Psychiatrica Scandinavica, 2022, 146, 215-226.	2.2	7
20	Reelin Alterations, Behavioral Phenotypes, and Brain Anomalies in Schizophrenia: A Systematic Review of Insights From Rodent Models. Frontiers in Neuroanatomy, 2022, 16, 844737.	0.9	8
21	Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nature Neuroscience, 2022, 25, 421-432.	7.1	75
22	Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naÃ <sup>-</sup> ve schizophrenia. Brain, Behavior, and Immunity, 2022, 103, 37-49.	2.0	4
23	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
24	Toward Understanding of Suicidality in a Spanish Clinical Population: Validation of the European Spanish Version of the Interpersonal Needs Questionnaire. Psychopathology, 2022, 55, 16-27.	1.1	0
25	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. Frontiers in Psychiatry, 2022, 13, 828376.	1.3	1
26	Longitudinal effects of cannabis use on attentional processes in patients with first episode of psychosis. Schizophrenia Research, 2022, 244, 71-80.	1.1	1
27	Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-NaÃ`ve First-Episode Psychosis. International Journal of Neuropsychopharmacology, 2022, 25, 795-806.	1.0	5
28	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. Schizophrenia Research, 2022, 246, 30-38.	1.1	3
29	Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2022, 15, 117-133.	0.2	0
30	A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs, 2022, 36, 659-679.	2.7	38
31	Epigenome-wide meta-analysis of blood DNA methylation and its association with subcortical volumes: findings from the ENIGMA Epigenetics Working Group. Molecular Psychiatry, 2021, 26, 3884-3895.	4.1	34
32	Entire duration of active psychosis and neurocognitive performance in <scp>firstâ€episode nonâ€affective</scp> psychosis. Microbial Biotechnology, 2021, 15, 1266-1275.	0.9	0
33	Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study. Molecular Psychiatry, 2021, 26, 5307-5319.	4.1	18
34	Glossary on atmospheric electricity and its effects on biology. International Journal of Biometeorology, 2021, 65, 5-29.	1.3	9
35	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. Brain, Behavior, and Immunity, 2021, 91, 673-682.	2.0	15
36	Long term cortical thickness changes after a first episode of non- affective psychosis: The 10Âyear follow-up of the PAFIP cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110180.	2.5	8

#	Article	IF	CITATIONS
37	The burden of disease in early schizophrenia – a systematic literature review. Current Medical Research and Opinion, 2021, 37, 109-121.	0.9	34
38	A network analysis approach to functioning problems in first psychotic episodes and their relationship with duration of untreated illness: Findings from the PAFIP cohort. Journal of Psychiatric Research, 2021, 136, 483-491.	1.5	3
39	COVID-19 Infection During Pregnancy and Risk of Neurodevelopmental Disorders in Offspring: Time for Collaborative Research. Biological Psychiatry, 2021, 89, e29-e30.	0.7	21
40	Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort. International Journal of Neuropsychopharmacology, 2021, 24, 1-7.	1.0	12
41	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	6.0	136
42	Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis. Psychological Medicine, 2021, 51, 340-350.	2.7	23
43	Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort. Psychological Medicine, 2021, 51, 264-277.	2.7	15
44	COVID-19 una oportunidad única para explorar la relación entre la infección prenatal materna, el desarrollo cerebral y los trastornos neuropsiquiátricos en la descendencia. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 1-3.	1.0	6
45	Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. Journal of Psychiatric Research, 2021, 134, 150-157.	1.5	7
46	Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Frontiers in Pharmacology, 2021, 12, 646701.	1.6	24
47	Prognostic significance of psychotic relapse in patients with first-episode acute and transient psychosis: New empirical support for ICD-11. Journal of Psychiatric Research, 2021, 137, 486-490.	1.5	5
48	Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. European Neuropsychopharmacology, 2021, 47, 74-85.	0.3	7
49	In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis. Neuroscience and Biobehavioral Reviews, 2021, 125, 535-568.	2.9	30
50	Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. International Journal of Environmental Research and Public Health, 2021, 18, 8133.	1.2	7
51	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 157-163.	1.0	9
52	Predictive value of prolactin in first episode psychosis at ten years follow-up. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 179-180.	1.0	1
53	Stability of schizophrenia diagnosis in a 10â€year longitudinal study on first episode of nonâ€affective psychosis: Conclusions from the PAFIP cohort. Acta Psychiatrica Scandinavica, 2021, 144, 342-357.	2.2	1
54	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 157-163.	0.2	4

#	Article	IF	CITATIONS
55	Predictive value of prolactin in first episode psychosis at ten years follow-up. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 179-180.	0.2	0
56	Prolactin, metabolic and immune parameters in naÃ⁻ve subjects with a first episode of psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110332.	2.5	6
57	Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110309.	2.5	1
58	Metabolic syndrome in antipsychotic-naÃ <sup>-</sup> ve patients with first-episode psychosis: a systematic review and meta-analysis. Psychological Medicine, 2021, 51, 2307-2320.	2.7	24
59	Predictors of diagnostic stability in brief psychotic disorders: Findings from a 3â€year longitudinal study. Acta Psychiatrica Scandinavica, 2021, 144, 578-588.	2.2	4
60	Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. Journal of Affective Disorders, 2021, 295, 173-182.	2.0	32
61	COVID-19 una oportunidad única para explorar la relación entre la infección prenatal materna, el desarrollo cerebral y los trastornos neuropsiquiátricos en la descendencia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 1-3.	0.2	0
62	Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology, 2021, 238, 329-340.	1.5	42
63	Understanding the Influence of Personality Traits on Risk of Suicidal Behaviour in Schizophrenia Spectrum Disorders: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 4604.	1.0	1
64	BOLD Coupling between Lesioned and Healthy Brain Is Associated with Glioma Patients' Recovery. Cancers, 2021, 13, 5008.	1.7	8
65	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. Molecular Psychiatry, 2020, 25, 584-602.	4.1	49
66	Using Machine Learning and Structural Neuroimaging to Detect First Episode Psychosis: Reconsidering the Evidence. Schizophrenia Bulletin, 2020, 46, 17-26.	2.3	76
67	Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. Molecular Psychiatry, 2020, 25, 2355-2372.	4.1	22
68	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. Schizophrenia Bulletin, 2020, 46, 432-441.	2.3	56
69	Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. JAMA Psychiatry, 2020, 77, 420.	6.0	54
70	M167. MACHINE LEARNING CLASSIFICATION OF FIRST-EPISODE PSYCHOSIS USING CORTICAL THICKNESS IN A LARGE MULTICENTER MRI STUDY. Schizophrenia Bulletin, 2020, 46, S200-S200.	2.3	0
71	S101. DIFFERENTIATING NON-AFFECTIVE ACUTE REMITTING PSYCHOSIS (NARP) FROM SCHIZOPHRENIA IN FIRST-EPISODE PSYCHOSIS: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT. Schizophrenia Bulletin, 2020, 46, S72-S73.	2.3	2
72	Needs of people with psychosis and their caregivers: "In their own voice― Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2020, 13, 80-89.	0.2	5

#	Article	IF	CITATIONS
73	A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. European Neuropsychopharmacology, 2020, 39, 46-55.	0.3	19
74	Data of a meta-analysis on pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia. Data in Brief, 2020, 31, 105904.	0.5	5
75	Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. Clinical Drug Investigation, 2020, 40, 861-871.	1.1	2
76	Grip Strength, Neurocognition, and Social Functioning in People WithType-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia. Frontiers in Psychology, 2020, 11, 525231.	1.1	9
77	Understanding sex differences in long-term outcomes after a first episode of psychosis. NPJ Schizophrenia, 2020, 6, 33.	2.0	36
78	Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-NaÃ <sup>-</sup> ve Non-Affective First Episode Psychosis Individuals: A 3-Month Study. International Journal of Molecular Sciences, 2020, 21, 6106.	1.8	6
79	Mental health and the SARS-CoV-2 pandemic. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2020, 13, 55-56.	0.2	0
80	M97. PREDICTORS OF TRANSITION TO SCHIZOPHRENIA IN BRIEF PSYCHOTIC DISORDER: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT. Schizophrenia Bulletin, 2020, 46, S171-S172.	2.3	0
81	Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 90-94.	1.0	117
82	Childhood trauma and substance use underlying psychosis: a systematic review. Högre Utbildning, 2020, 11, 1748342.	1.4	17
83	Mental health and the SARS-CoV-2 pandemic. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 55-56.	1.0	19
84	Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program. Data in Brief, 2020, 30, 105599.	0.5	0
85	Breve salutación y visión compartida. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 53-54.	1.0	0
86	Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users. Journal of Biopharmaceutical Statistics, 2020, 30, 916-940.	0.4	3
87	Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophrenia Research, 2020, 222, 88-96.	1.1	29
88	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	6.0	450
89	Neuroharmony: A new tool for harmonizing volumetric MRI data from unseen scanners. NeuroImage, 2020, 220, 117127.	2.1	48
90	Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning. Brain, 2020, 143, 1027-1038.	3.7	158

#	Article	IF	CITATIONS
91	Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. International Journal of Neuropsychopharmacology, 2020, 23, 217-229.	1.0	40
92	Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study. Schizophrenia Research, 2020, 220, 240-247.	1.1	11
93	Brain grey matter abnormalities in first episode non-affective psychosis patients with suicidal behaviours: The role of neurocognitive functioning. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109948.	2.5	14
94	Necesidades de las personas con psicosis y sus cuidadores: «en voz propia». Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 80-89.	1.0	5
95	Prevalence of hepatitis C in patients with non-affective psychotic disorders. Revista Espanola De Enfermedades Digestivas, 2020, 112, 550-554.	0.1	8
96	Suicidal Behavior and Personality Traits Contribute to Disability in Firstâ€episode Psychosis: A 1‥ear Followâ€up Study. Suicide and Life-Threatening Behavior, 2019, 49, 798-810.	0.9	9
97	Antipsicóticos inyectables de liberación prolongada para el tratamiento de la esquizofrenia en España. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 92-105.	1.0	23
98	Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients. Archives of Women's Mental Health, 2019, 22, 367-373.	1.2	22
99	Visual memory dysfunction as a neurocognitive endophenotype in bipolar disorder patients and their unaffected relatives. Evidence from a 5-year follow-up Valencia study Journal of Affective Disorders, 2019, 257, 31-37.	2.0	12
100	Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 92-105.	0.2	3
101	S68. UNALTERED FRONTAL AND PREFRONTAL BRAIN RESPONSE DURING WORK MEMORY TASKS IN PATIENTS WITH A FIRST EPISODE PSYCHOSIS META-ANALYSIS STUDY. Schizophrenia Bulletin, 2019, 45, S332-S333.	2.3	0
102	Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study. Journal of Psychopharmacology, 2019, 33, 284-294.	2.0	18
103	10Kin1day: A Bottom-Up Neuroimaging Initiative. Frontiers in Neurology, 2019, 10, 425.	1.1	15
104	Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. Science Advances, 2019, 5, eaau9093.	4.7	22
105	Longitudinal studies of functional magnetic resonance imaging in first-episode psychosis: A systematic review. European Psychiatry, 2019, 59, 60-69.	0.1	24
106	Time dependent expression of the blood biomarkers EIF2D and TOX in patients with schizophrenia. Brain, Behavior, and Immunity, 2019, 80, 909-915.	2.0	3
107	Sex differences in gene expression related to antipsychotic induced weight gain. PLoS ONE, 2019, 14, e0215477.	1.1	13
108	Altered gene expression in antipsychotic-induced weight gain. NPJ Schizophrenia, 2019, 5, 7.	2.0	16

#	Article	IF	CITATIONS
109	CIBERSAM: Ten years of collaborative translational research in mental disorders. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 1-8.	0.2	5
110	Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment. JAMA Psychiatry, 2019, 76, 864.	6.0	43
111	Patterns of recovery course in early intervention for FIRST episode non-affective psychosis patients: The role of timing. Schizophrenia Research, 2019, 209, 245-254.	1.1	4
112	Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics. Translational Psychiatry, 2019, 9, 306.	2.4	16
113	Multimodal Integration of Brain Images for MRI-Based Diagnosis in Schizophrenia. Frontiers in Neuroscience, 2019, 13, 1203.	1.4	26
114	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
115	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. American Journal of Psychiatry, 2019, 176, 21-28.	4.0	127
116	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	0.7	5
117	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 1-8.	1.0	68
118	Understanding the direct and indirect costs of a first episode of psychosis program: Insights from PAFIP of Cantabria, Spain, during the first year of intervention. Microbial Biotechnology, 2019, 13, 1182-1190.	0.9	11
119	Insight and risk of suicidal behaviour in two first-episode psychosis cohorts: Effects of previous suicide attempts and depression. Schizophrenia Research, 2019, 204, 80-89.	1.1	28
120	Verbal memory and voxel based morphometry in first episode non-affective psychosis: A process oriented approach Neuropsychology, 2019, 33, 568-580.	1.0	1
121	Long-Term Grey Matter Changes in First Episode Psychosis: A Systematic Review. Psychiatry Investigation, 2019, 16, 336-345.	0.7	22
122	Targeting recovery in first episode psychosis: The importance of neurocognition and premorbid adjustment in a 3-year longitudinal study. Schizophrenia Research, 2018, 195, 320-326.	1.1	18
123	Premorbid IQ subgroups in first episode non affective psychosis patients: Long-term sex differences in function and neurocognition. Schizophrenia Research, 2018, 197, 370-377.	1.1	26
124	The effect of excess weight on circulating inflammatory cytokines in drug-naÃ <sup>-</sup> ve first-episode psychosis individuals. Journal of Neuroinflammation, 2018, 15, 63.	3.1	19
125	F81. AGE OF ONSET OF CANNABIS USE AND COGNITIVE FUNCTION IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS PATIENTS: 3-YEAR FOLLOW-UP OUTCOME. Schizophrenia Bulletin, 2018, 44, S251-S251.	2.3	0
126	Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. European Psychiatry, 2018, 52, 29-37.	0.1	17

#	Article	IF	CITATIONS
127	Tobacco smoking and its association with cognition in first episode psychosis patients. Schizophrenia Research, 2018, 192, 269-273.	1.1	34
128	Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naÃ <sup>-</sup> ve patients with a first-episode of non-affective psychosis. Psychopharmacology, 2018, 235, 245-255.	1.5	30
129	A polygenic risk score analysis of psychosis endophenotypes across brain functional, structural, and cognitive domains. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 21-34.	1.1	57
130	Low-density lipoprotein cholesterol and suicidal behaviour in a large sample of first-episode psychosis patients. World Journal of Biological Psychiatry, 2018, 19, S158-S161.	1.3	17
131	06.7. COMMON NEUROANATOMICAL ABNORMALITIES IN FIRST EPISODE PSYCHOSIS ACROSS SEVERAL INDEPENDENT SAMPLES. Schizophrenia Bulletin, 2018, 44, S92-S92.	2.3	0
132	T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S184-S184.	2.3	0
133	F124. SEX DIFFERENCES IN OUTCOME IN FIRST EPISODE PSYCHOSIS PATIENTS: A 10-YEAR FOLLOW-UP STUDY. Schizophrenia Bulletin, 2018, 44, S268-S268.	2.3	0
134	S124. RECOVERY TRAJECTORIES IN FIRST EPISODE PSYCHOSIS PATIENTS: THE ROLE OF TIMING. Schizophrenia Bulletin, 2018, 44, S373-S373.	2.3	0
135	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget, 2018, 9, 30869-30882.	0.8	9
136	S125. THE DYNAMIC RELATIONSHIP BETWEEN INSIGHT AND SUICIDAL BEHAVIOUR IN FIRST EPISODE PSYCHOSIS PATIENTS OVER 3-YEAR FOLLOW-UP. Schizophrenia Bulletin, 2018, 44, S374-S374.	2.3	2
137	Diverse definitions of the early course of schizophrenia—a targeted literature review. NPJ Schizophrenia, 2018, 4, 21.	2.0	52
138	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. International Journal of Neuropsychopharmacology, 2018, 21, 1090-1101.	1.0	16
139	Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders. Biochemical Pharmacology, 2018, 157, 258-265.	2.0	15
140	Age of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-up. Schizophrenia Research, 2018, 201, 159-166.	1.1	6
141	F101. CANNABIS USE AND HEPATIC STEATOSIS IN PSYCHOSIS: RESULTS FROM A 3-YEAR LONGITUDINAL STUDY. Schizophrenia Bulletin, 2018, 44, S259-S259.	2.3	0
142	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	0.7	627
143	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. American Journal of Gastroenterology, 2018, 113, 1639-1648.	0.2	72
144	Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naÃ⁻ve first episode psychosis individuals: A 3†months randomized study. Schizophrenia Research, 2018, 202, 226-233.	1.1	37

#	Article	IF	CITATIONS
145	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
146	Blood Gene Expression Profile Predicts Response to Antipsychotics. Frontiers in Molecular Neuroscience, 2018, 11, 73.	1.4	18
147	Gain-of-function mutations in DNMT3A in patients with paraganglioma. Genetics in Medicine, 2018, 20, 1644-1651.	1.1	73
148	Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders. British Journal of Psychiatry, 2018, 213, 535-541.	1.7	37
149	S173. GREY MATTER VOLUME DEFFICITS IN PATIENTS WITH A FIRST EPISODE NON-AFFECTIVE PSYCHOSIS AND SUICIDE RELATED BEHAVIOUR. Schizophrenia Bulletin, 2018, 44, S392-S392.	2.3	0
150	The dynamic relationship between insight and suicidal behavior in first episode psychosis patients over 3-year follow-up. European Neuropsychopharmacology, 2018, 28, 1161-1172.	0.3	20
151	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell, 2018, 173, 1705-1715.e16.	13.5	623
152	The right occipital lobe and poor insight in first-episode psychosis. PLoS ONE, 2018, 13, e0197715.	1.1	16
153	T72. VERBAL MEMORY AND VOXEL BASED MORPHOMETRY IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS: A PROCESS ORIENTED APPROACH. Schizophrenia Bulletin, 2018, 44, S142-S142.	2.3	0
154	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5.8	250
155	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. Revista De PsiquiatrÃa Y Salud Mental, 2017, 10, 4-20.	1.0	18
156	Disability multilevel modelling in first episodes of psychosis at 3-year follow-up. Schizophrenia Research, 2017, 185, 101-106.	1.1	3
157	Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophrenia Research, 2017, 189, 134-141.	1.1	20
158	Validation of schizophrenia gene expression profile in a preclinical model of maternal infection during pregnancy. Schizophrenia Research, 2017, 189, 217-218.	1.1	1
159	Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology, 2017, 234, 2563-2570.	1.5	27
160	Cuando la asistencia no sigue a la evidencia: el caso de la falta de programas de intervención temprana en psicosis en España. Revista De PsiquiatrÃa Y Salud Mental, 2017, 10, 78-86.	1.0	37
161	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2017, 10, 4-20.	0.2	7
162	Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies. Systematic Reviews, 2017, 6, 69.	2.5	24

#	Article	IF	CITATIONS
163	Enhanced Stress Response in 5-HT <sub>1A</sub> R Overexpressing Mice: Altered HPA Function and Hippocampal Long-Term Potentiation. ACS Chemical Neuroscience, 2017, 8, 2393-2401.	1.7	10
164	Longitudinal investigation of the parietal lobe anatomy in bipolar disorder and its association with general functioning. Psychiatry Research - Neuroimaging, 2017, 267, 22-31.	0.9	17
165	Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 315-323.	1.8	32
166	Human subcortical brain asymmetries in 15,847 people worldwide reveal effects of age and sex. Brain Imaging and Behavior, 2017, 11, 1497-1514.	1.1	144
167	The effects of tobacco smoking on age of onset of psychosis and psychotic symptoms in a first-episode psychosis population. Addiction, 2017, 112, 526-532.	1.7	8
168	Multi-center MRI prediction models: Predicting sex and illness course in first episode psychosis patients. NeuroImage, 2017, 145, 246-253.	2.1	43
169	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	9.4	838
170	Common and distinct structural features of schizophrenia and bipolar disorder: The European Network on Psychosis, Affective disorders and Cognitive Trajectory (ENPACT) study. PLoS ONE, 2017, 12, e0188000.	1.1	74
171	Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences. PLoS ONE, 2017, 12, e0183613.	1.1	12
172	Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging. Lecture Notes in Computer Science, 2017, 10541, 371-378.	1.0	4
173	Evidence for Trait Related Theory of Mind Impairment in First Episode Psychosis Patients and Its Relationship with Processing Speed: A 3 Year Follow-up Study. Frontiers in Psychology, 2016, 7, 592.	1.1	21
174	Counterfactual Reasoning in Non-psychotic First-Degree Relatives of People with Schizophrenia. Frontiers in Psychology, 2016, 7, 665.	1.1	7
175	Environmental factors linked to depression vulnerability are associated with altered cerebellar resting-state synchronization. Scientific Reports, 2016, 6, 37384.	1.6	21
176	Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2016, 9, 158-173.	0.2	23
177	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
178	Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurology and Therapy, 2016, 5, 105-130.	1.4	22
179	Homocysteine and cognition: A systematic review of 111 studies. Neuroscience and Biobehavioral Reviews, 2016, 69, 280-298.	2.9	51
180	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology, 2016, 233, 3947-3952.	1.5	40

#	Article	IF	CITATIONS
181	Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 619-628.	1.8	28
182	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv132.	1.0	50
183	Evidence for Genetic Overlap Between Schizophrenia and Age at First Birth in Women. JAMA Psychiatry, 2016, 73, 497.	6.0	51
184	Towards a blood-based diagnostic panel for bipolar disorder. Brain, Behavior, and Immunity, 2016, 52, 49-57.	2.0	59
185	Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos. Revista De PsiquiatrÃa Y Salud Mental, 2016, 9, 158-173.	1.0	47
186	Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas, 2016, 83, 83-93.	1.0	39
187	Variations in Disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis. Brain Imaging and Behavior, 2016, 10, 629-635.	1.1	6
188	Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-Episode Nonaffective Psychosis Individuals. Journal of Clinical Psychiatry, 2016, 77, 492-500.	1.1	47
189	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. American Journal of Psychiatry, 2015, 172, 617-629.	4.0	150
190	Grey matter volume differences in non-affective psychosis and the effects of age of onset on grey matter volumes: A voxelwise study. Schizophrenia Research, 2015, 164, 74-82.	1.1	26
191	Disability in bipolar I disorder: The 36-item World Health Organization Disability Assessment Schedule 2.0. Journal of Affective Disorders, 2015, 174, 353-360.	2.0	35
192	Season of birth and subclinical psychosis: Systematic review and meta-analysis of new and existing data. Psychiatry Research, 2015, 225, 227-235.	1.7	8
193	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	13.7	772
194	Schizophrenia Gene Expression Profile Reverted to Normal Levels by Antipsychotics. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	37
195	Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms. Psychiatry Research - Neuroimaging, 2015, 233, 112-119.	0.9	34
196	Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. Frontiers in Physiology, 2015, 6, 108.	1.3	35
197	Inpatient Treatment for Anorexia Nervosa. Journal of Psychiatric Practice, 2015, 21, 49-59.	0.3	19
198	Progressive Structural Brain Changes and NRG1 Gene Variants in First-Episode Nonaffective Psychosis. Neuropsychobiology, 2015, 71, 103-111.	0.9	9

#	Article	IF	CITATIONS
199	Suicidal behaviour in first-episode non-affective psychosis: Specific risk periods and stage-related factors. European Neuropsychopharmacology, 2015, 25, 2278-2288.	0.3	58
200	Dysbindin gene variability is associated with cognitive abnormalities in first-episode non-affective psychosis. Cognitive Neuropsychiatry, 2015, 20, 144-156.	0.7	17
201	A cross-sectional and longitudinal structural magnetic resonance imaging study of the post-central gyrus in first-episode schizophrenia patients. Psychiatry Research - Neuroimaging, 2015, 231, 42-49.	0.9	16
202	Birth Weight and Adult IQ, but Not Anxious-Depressive Psychopathology, Are Associated with Cortical Surface Area: A Study in Twins. PLoS ONE, 2015, 10, e0129616.	1.1	6
203	Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review. Current Neuropharmacology, 2015, 13, 422-434.	1.4	39
204	Alzheimer's Disease and Cancer: Current Epidemiological Evidence for a Mutual Protection. Neuroepidemiology, 2014, 42, 121-122.	1.1	23
205	Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. International Journal of Neuropsychopharmacology, 2014, 17, 41-51.	1.0	94
206	Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies. Psychotherapy and Psychosomatics, 2014, 83, 89-105.	4.0	164
207	Clinical Spanish Norms of the Stroop Test for Traumatic Brain Injury and Schizophrenia. Spanish Journal of Psychology, 2014, 17, E96.	1.1	6
208	Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1Âyear. Psychopharmacology, 2014, 231, 357-366.	1.5	21
209	Immune system: A possible nexus between cannabinoids and psychosis. Brain, Behavior, and Immunity, 2014, 40, 269-282.	2.0	47
210	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	1.1	696
211	Lack of insight 3years after first-episode psychosis: An unchangeable illness trait determined from first presentation?. Schizophrenia Research, 2014, 157, 271-277.	1.1	21
212	Differential associations of cognitive insight components with pretreatment characteristics in first-episode psychosis. Psychiatry Research, 2014, 215, 308-313.	1.7	13
213	Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis. Schizophrenia Research, 2014, 159, 90-94.	1.1	34
214	A Genome-wide Association Analysis of a Broad Psychosis Phenotype Identifies Three Loci for Further Investigation. Biological Psychiatry, 2014, 75, 386-397.	0.7	44
215	No sex differences in neuropsychological performance in first episode psychosis patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 149-154.	2.5	47
216	A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis. Psychiatry Investigation, 2014, 11, 186.	0.7	16

#	Article	IF	CITATIONS
217	The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. BMC Psychiatry, 2013, 13, 127.	1.1	37
218	Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 2013, 45, 1150-1159.	9.4	1,395
219	Course of cognitive deficits in first episode of non-affective psychosis: A 3-year follow-up study. Schizophrenia Research, 2013, 150, 121-128.	1.1	34
220	Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 162-167.	2.5	35
221	BDNF Val66Met variants and brain volume changes in non-affective psychosis patients and healthy controls: A 3year follow-up study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 201-206.	2.5	6
222	Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. Psychiatry Research, 2013, 206, 181-187.	1.7	33
223	Predictors of neurocognitive impairment at 3years after a first episode non-affective psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 23-28.	2.5	18
224	Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial. Schizophrenia Research, 2013, 147, 375-382.	1.1	21
225	The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year longitudinal study. Psychiatry Research, 2013, 209, 302-308.	1.7	54
226	Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. Psychopharmacology, 2013, 227, 615-625.	1.5	23
227	Aripiprazole, Ziprasidone, and Quetiapine in the Treatment of First-Episode Nonaffective Psychosis. Journal of Clinical Psychopharmacology, 2013, 33, 215-220.	0.7	20
228	Neuroanatomical Differences between First-Episode Psychosis Patients with and without Neurocognitive Deficit: A 3-Year Longitudinal Study. Frontiers in Psychiatry, 2013, 4, 134.	1.3	9
229	Chapter 10 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients. , 2013, , 107-113.		0
230	Long-Term Effect of Haloperidol, Olanzapine, and Risperidone on Plasma Prolactin Levels in Patients With First-Episode Psychosis. Journal of Clinical Psychopharmacology, 2012, 32, 804-808.	0.7	24
231	White Matter Abnormalities in Veterans With Mild Traumatic Brain Injury. American Journal of Psychiatry, 2012, 169, 1284-1291.	4.0	136
232	Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis. Current Pharmaceutical Design, 2012, 18, 5024-5035.	0.9	48
233	Homocysteine and cognition in first-episode psychosis patients. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 557-564.	1.8	51
234	Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. Journal of Psychiatric Research, 2012, 46, 1099-1105.	1.5	118

#	Article	IF	CITATIONS
235	Identifying attentional deficits in people with first-episode psychosis with the Scale for the Assessment of Negative Symptoms attention subscale: is it possible?. Comprehensive Psychiatry, 2012, 53, 701-705.	1.5	5
236	Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. Schizophrenia Research, 2012, 138, 240-247.	1.1	56
237	Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Schizophrenia Research, 2012, 141, 22-28.	1.1	28
238	One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients. Psychiatry Research - Neuroimaging, 2012, 202, 80-83.	0.9	9
239	Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology, 2012, 219, 225-233.	1.5	24
240	Chapter 9 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients. , 2012, , 103-109.		1
241	A Digit Symbol Coding Task as a Screening Instrument for Cognitive Impairment in First-Episode Psychosis. Archives of Clinical Neuropsychology, 2011, 26, 48-58.	0.3	48
242	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: A comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). Schizophrenia Research, 2011, 130, 137-142.	1.1	44
243	Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naĀ ve first-episode psychosis patients. Schizophrenia Research, 2011, 131, 82-89.	1.1	7
244	Straight gyrus morphology in first-episode schizophrenia-spectrum patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 84-90.	2.5	4
245	Sex-specific variation of MRI-based cortical morphometry in adult healthy volunteers: The effect on cognitive functioning. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 616-623.	2.5	19
246	Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Research, 2011, 185, 286-289.	1.7	23
247	No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncology, The, 2011, 12, 604-608.	5.1	122
248	Insight dimensions in first-episode psychosis patients: clinical, cognitive, pre-morbid and socio-demographic correlates. Microbial Biotechnology, 2011, 5, 140-149.	0.9	31
249	Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. Journal of Psychiatric Research, 2011, 45, 763-769.	1.5	21
250	Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. Journal of Psychopharmacology, 2011, 25, 744-754.	2.0	15
251	Effects of Family Psychoeducation on Expressed Emotion and Burden of Care in First-Episode Psychosis: A Prospective Observational Study. Spanish Journal of Psychology, 2010, 13, 389-395.	1.1	32
252	Effect of FTO, SH2B1, LEP, and LEPR Polymorphisms on Weight Gain Associated With Antipsychotic Treatment. Journal of Clinical Psychopharmacology, 2010, 30, 661-666.	0.7	44

#	Article	IF	CITATIONS
253	Insular cortex morphometry in first-episode schizophrenia-spectrum patients: Diagnostic specificity and clinical correlations. Journal of Psychiatric Research, 2010, 44, 314-320.	1.5	22
254	Insular cortex thinning in first episode schizophrenia patients. Psychiatry Research - Neuroimaging, 2010, 182, 216-222.	0.9	25
255	Temporal pole morphology in first-episode schizophrenia patients:. Psychiatry Research - Neuroimaging, 2010, 184, 189-191.	0.9	8
256	Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. Brain Research, 2010, 1317, 297-304.	1.1	71
257	White Matter Integrity and Cognitive Impairment in First-Episode Psychosis. American Journal of Psychiatry, 2010, 167, 451-458.	4.0	131
258	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). Schizophrenia Research, 2010, 116, 243-251.	1.1	55
259	Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophrenia Research, 2010, 116, 16-19.	1.1	56
260	First-episode schizophrenia patients neuropsychologically within the normal limits: Evidence of deterioration in speed of processing. Schizophrenia Research, 2010, 119, 18-26.	1.1	34
261	Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naÃ⁻ve psychotic sample. Schizophrenia Research, 2010, 121, 207-212.	1.1	37
262	Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophrenia Research, 2010, 124, 142-151.	1.1	52
263	Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Research, 2010, 175, 189-194.	1.7	29
264	Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: Clinical-onset implications. Psychiatry Research, 2010, 179, 291-296.	1.7	46
265	White matter defects in first episode psychosis patients: A voxelwise analysis of diffusion tensor imaging. Neurolmage, 2010, 49, 199-204.	2.1	92
266	Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia. NeuroImage, 2010, 53, 1016-1022.	2.1	41
267	Longitudinal course of cognition in schizophrenia. British Journal of Psychiatry, 2009, 195, 84-84.	1.7	2
268	Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia. Evidence-Based Mental Health, 2009, 12, 55-55.	2.2	0
269	Assessment of the increase in variability when combining volumetric data from different scanners. Human Brain Mapping, 2009, 30, 355-368.	1.9	48
270	A Neuregulin 1 Variant Is Associated with Increased Lateral Ventricle Volume in Patients with First-Episode Schizophrenia. Biological Psychiatry, 2009, 65, 535-540.	0.7	54

#	Article	IF	CITATIONS
271	Glucose and lipid disturbances after 1Âyear of antipsychotic treatment in a drug-naÃ⁻ve population. Schizophrenia Research, 2009, 107, 115-121.	1.1	83
272	Specific brain structural abnormalities in first-episode schizophrenia Schizophrenia Research, 2009, 115, 191-201.	1.1	32
273	Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. Health and Quality of Life Outcomes, 2009, 7, 28.	1.0	37
274	Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode Psychosis. Journal of Clinical Psychiatry, 2009, 70, 717-729.	1.1	58
275	Cognitive functioning and negative symptoms in first episode schizophrenia: Different patterns of correlates. Neurotoxicity Research, 2008, 14, 227-235.	1.3	13
276	Treatment of the first episode of schizophrenia: An update on pharmacologic and psychological interventions. Current Psychiatry Reports, 2008, 10, 202-209.	2.1	15
277	Catecholâ€ <i>O</i> â€methyltransferase <i>Val158Met</i> polymorphism and clinical characteristics in first episode nonâ€affective psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 550-556.	1.1	23
278	Epidemiological factors associated with treated incidence of firstâ€episode nonâ€affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Microbial Biotechnology, 2008, 2, 178-187.	0.9	131
279	Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis. Psychiatry Research - Neuroimaging, 2008, 162, 167-171.	0.9	5
280	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia. Schizophrenia Research, 2008, 99, 139-148.	1.1	78
281	Weight gain induced by haloperidol, risperidone and olanzapine after 1Âyear: Findings of a randomized clinical trial in a drug-naÃ <sup>-</sup> ve population. Schizophrenia Research, 2008, 99, 13-22.	1.1	102
282	1-year follow-up study of cognitive function in first-episode non-affective psychosis. Schizophrenia Research, 2008, 104, 165-174.	1.1	42
283	Interleukin-12 plasma levels in drug-naÃ <sup>-</sup> ve patients with a first episode of psychosis: Effects of antipsychotic drugs. Psychiatry Research, 2008, 158, 206-216.	1.7	49
284	Effect of antipsychotic drugs on brain morphometry Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1936-1943.	2.5	46
285	Lack of influence of COMT Val158Met genotype on cognition in first-episode non-affective psychosis. Schizophrenia Research, 2008, 102, 206-209.	1.1	15
286	Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders. CNS Drugs, 2008, 22, 547-562.	2.7	229
287	Effect of Antipsychotics on Peptides Involved in Energy Balance in Drug-Naive Psychotic Patients After 1 Year of Treatment. Journal of Clinical Psychopharmacology, 2008, 28, 289-295.	0.7	74
288	Preserved Orbitofrontal Function in First-Episode Schizophrenia. Journal of Nervous and Mental Disease, 2008, 196, 67-70.	0.5	4

#	Article	IF	CITATIONS
289	Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment. Canadian Journal of Psychiatry, 2008, 53, 839-47.	0.9	11
290	Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. British Journal of Psychiatry, 2007, 191, s107-s110.	1.7	108
291	Neuropsychological functioning and brain structure in schizophrenia. International Review of Psychiatry, 2007, 19, 325-336.	1.4	62
292	Low-activity allele of Catechol-O-Methyltransferase (COMTL) is associated with increased lateral ventricles in patients with first episode non-affective psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1514-1518.	2.5	17
293	Reduced thalamic volume in first-episode non-affective psychosis: Correlations with clinical variables, symptomatology and cognitive functioning. NeuroImage, 2007, 35, 1613-1623.	2.1	66
294	The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. Schizophrenia Research, 2007, 91, 226-237.	1.1	85
295	Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia. Schizophrenia Research, 2007, 91, 87-96.	1.1	76
296	Predictors of acute treatment response in patients with a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research, 2007, 41, 659-666.	1.5	87
297	Cognitive dimensions in first-episode schizophrenia spectrum disorders. Journal of Psychiatric Research, 2007, 41, 968-977.	1.5	77
298	A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug-Naive, First-Episode Psychosis Patients Treated With Haloperidol, Olanzapine, or Risperidone. Journal of Clinical Psychiatry, 2007, 68, 1733-1740.	1.1	87
299	Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 364-371.	1.8	38
300	Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 939-943.	1.1	15
301	Attenuation of Antipsychotic-Induced Weight Gain With Early Behavioral Intervention in Drug-Naive First-Episode Psychosis Patients. Journal of Clinical Psychiatry, 2006, 67, 1253-1260.	1.1	152
302	A Practical Clinical Trial Comparing Haloperidol, Risperidone, and Olanzapine for the Acute Treatment of First-Episode Nonaffective Psychosis. Journal of Clinical Psychiatry, 2006, 67, 1511-1521.	1.1	138
303	Alcohol Misuse and Mood Disorders Following Traumatic Brain Injury. Archives of General Psychiatry, 2005, 62, 742.	13.8	116
304	Prefrontal cognitive functions in stabilized first-episode patients with schizophrenia spectrum disorders: A dissociation between dorsolateral and orbitofrontal functioning. Schizophrenia Research, 2005, 77, 279-288.	1.1	79
305	Major Depression Following Traumatic Brain Injury. Archives of General Psychiatry, 2004, 61, 42.	13.8	637
306	Morphometry of the Superior Temporal Plane In Schizophrenia: Relationship to Clinical Correlates. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 284-294.	0.9	26

#	Article	IF	CITATIONS
307	Temporal pole morphology and psychopathology in males with schizophrenia. Psychiatry Research - Neuroimaging, 2004, 132, 107-115.	0.9	43
308	Morphology of the lateral superior temporal gyrus in neuroleptic naıÌ`ve patients with schizophrenia: relationship to symptoms. Schizophrenia Research, 2003, 60, 173-181.	1.1	52
309	Emotions in Unmedicated Patients With Schizophrenia During Evaluation With Positron Emission Tomography. American Journal of Psychiatry, 2003, 160, 1775-1783.	4.0	182
310	Morphology of the ventral frontal cortex in schizophrenia: relationship with social dysfunction. Biological Psychiatry, 2002, 52, 1-8.	0.7	78
311	Sex differences in the absence of massa intermedia in patients with schizophrenia versus healthy controls. Schizophrenia Research, 2001, 48, 177-185.	1.1	46
312	Neural basis of novel and well-learned recognition memory in schizophrenia: A positron emission tomography study. Human Brain Mapping, 2001, 12, 219-231.	1.9	66
313	Neural Mechanisms of Anhedonia in Schizophrenia. JAMA - Journal of the American Medical Association, 2001, 286, 427.	3.8	214
314	Novel vs. Well-learned Memory for Faces: A Positron Emission Tomography Study. Journal of Cognitive Neuroscience, 2000, 12, 255-266.	1.1	39
315	Cerebral cortex: a topographic segmentation method using magnetic resonance imaging. Psychiatry Research - Neuroimaging, 2000, 100, 97-126.	0.9	66
316	An MRI-Based Parcellation Method for the Temporal Lobe. NeuroImage, 2000, 11, 271-288.	2.1	154
317	Regional frontal abnormalities in schizophrenia: a quantitative gray matter volume and cortical surface size study. Biological Psychiatry, 2000, 48, 110-119.	0.7	121
318	Regional cerebral blood flow in obsessive-compulsive patients with and without a chronic tic disorder. A SPECT study European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, 156-161.	1.8	42
319	Human Frontal Cortex: An MRI-Based Parcellation Method. NeuroImage, 1999, 10, 500-519.	2.1	122